Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:
”Pleased to share our commentary published in American Society of Clinical Oncology (ASCO) flagship journal Journal of Clinical Oncology for your quick Sunday morning read.
Is It Time to Retire the Unified Cancer of Unknown Primary Concept in the Precision Oncology Era?”
Title: Is It Time to Retire the Unified Cancer of Unknown Primary Concept in the Precision Oncology Era?
Authors: Vivek Subbiah, F. Anthony Greco
Vivek Subbiah was recognized among OncoDaily’s The 100 Most Influential People in Oncology in 2025, highlighting his contributions to the field of oncology.
Nominations for 100 Influential People in Oncology 2026 are now open, recognizing leaders, researchers, clinicians, innovators, advocates, and other individuals making a meaningful impact on oncology and cancer care.
Don’t miss the opportunity to nominate yourself, a colleague, or someone whose contributions deserve to be recognized.
Submit your nomination by September 15: 100 Influential People in Oncology 2026 – Nominations are Open!
Other articles featuring Vivek Subbiah on OncoDaily.